QCM Cayman’s Quest Diagnostics DGX Stock Holding History

QCM Cayman’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-3,280	Closed	-$322K	–	215
2017 Q1	$322K	Buy	+3,280	New	+$313K	0.06%	253
2016 Q3	–	Sell	-3,578	Closed	-$291K	–	240
2016 Q2	$291K	Buy	+3,578	New	+$272K	0.13%	137

Other funds holding DGX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

AJO LP Philadelphia, Pennsylvania $199M AUM 109.68% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

QCM Cayman's DGX Position: Q2 2017 in Review

QCM Cayman sold out of Quest Diagnostics (DGX) in Q2 2017, closing a stake of 3,280 shares — an estimated $322K sold.

QCM Cayman first reported a position in DGX in Q2 2016 and held it in 2 quarters. The position peaked at $322K in Q1 2017. 643 funds tracked by Wall St. Rank hold DGX as of Q2 2017.

QCM Cayman reported no remaining Quest Diagnostics position as of Q2 2017 after selling out during the quarter.
QCM Cayman sold 3,280 Quest Diagnostics shares in Q2 2017, an estimated $322K.
QCM Cayman first reported a position in Quest Diagnostics in Q2 2016 and held it in 2 quarters.
QCM Cayman's Quest Diagnostics position peaked at $322K in Q1 2017.
643 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2017.

Based on QCM Cayman's 13F filing for Q2 2017, filed 14 Aug 2017.